Gary S. Gillheeney Sells 5,585 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney sold 5,585 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $3.49, for a total transaction of $19,491.65. Following the completion of the sale, the chief executive officer now directly owns 3,039,194 shares in the company, valued at approximately $10,606,787.06. This represents a 0.18 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Organogenesis Stock Performance

Shares of ORGO stock opened at $3.57 on Wednesday. Organogenesis Holdings Inc. has a 12 month low of $2.16 and a 12 month high of $4.70. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The company has a market cap of $473.30 million, a P/E ratio of -59.50 and a beta of 1.73. The firm has a fifty day moving average price of $3.45 and a 200 day moving average price of $3.01.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Tuesday, November 12th. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11. The business had revenue of $115.18 million for the quarter, compared to the consensus estimate of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same quarter in the prior year, the business posted $0.02 EPS. Sell-side analysts predict that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Institutional Trading of Organogenesis

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ORGO. Verition Fund Management LLC grew its position in shares of Organogenesis by 542.8% in the 3rd quarter. Verition Fund Management LLC now owns 78,690 shares of the company’s stock valued at $225,000 after buying an additional 66,448 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Organogenesis by 19.6% during the second quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock worth $5,702,000 after purchasing an additional 333,123 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Organogenesis by 76.9% during the second quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock worth $6,353,000 after purchasing an additional 986,132 shares in the last quarter. Cubist Systematic Strategies LLC lifted its holdings in shares of Organogenesis by 1,350.3% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 94,705 shares of the company’s stock valued at $265,000 after purchasing an additional 88,175 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its position in shares of Organogenesis by 2.4% in the 2nd quarter. Acadian Asset Management LLC now owns 3,074,375 shares of the company’s stock valued at $8,605,000 after purchasing an additional 72,696 shares during the period. Institutional investors and hedge funds own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.